1. Introduction {#sec1}
===============

Acute lymphoblastic leukemia (ALL) remains one of the most challenging adults\' hematological malignancies \[[@B1]\]. With respect to therapy, the use of multiagent chemotherapy regimens for the treatment of acute lymphoblastic leukemia (ALL) is considered as a cancer success story in the pediatric setting \[[@B2]\], which have offered patients who once had a dismal prognosis a cure rate that approaches or exceeds 90% \[[@B3], [@B4]\]. For adults, the same magnitude of success has not been realized using similar strategies, and the cure rate of adults ALL is estimated to be between 20 and 40% \[[@B5], [@B6]\]. Adults\' patients tend to present with higher risk features at diagnosis, predisposing to chemotherapy resistance and disease relapses after initial achievement of complete remission (CR) \[[@B7]\]. On the other hand, within childhood ALL, older children have shown inferior outcomes, and within adults ALL, younger adults have shown superior outcomes. Retrospective studies focusing on patient\'s age 15 to 21 years showed that "Adolescents and Young Adults" (AYA) treated with adults ALL protocols have poorer outcomes than similarly aged patients treated with pediatric protocols \[[@B8]--[@B16]\]. Five-year event-free survival (EFS) for AYA treated with pediatric regimens ranges from 64% to 69% while in adult regimen it ranges from 34% to 49% \[[@B17]--[@B20]\].

In our country, adolescents aged between 15 and 18 years of age are referred either to pediatrics or to adults departments according to physician who firstly made the diagnoses either pediatrician or internist. This study was conducted to assess the outcome of different protocols applied by 2 different teams, namely, pediatrics and adults oncologists in the same age group (adolescent).

2. Patients and Methods {#sec2}
=======================

2.1. Study Eligibility {#sec2.1}
----------------------

We retrospectively reviewed files of 86 consecutive adolescent ALL patients aged 15--18 years old attended to outpatients clinic of pediatrics and adults medical oncology and hematological malignancy departments, South Egypt Cancer institute and pediatric oncology department in Sohag Cancer center, Egypt, from January 2003 to January 2010. We divided them into 2 groups according to their different treatment protocols. Group 1 (pediatrics protocol group) included patients treated with the adopted regimen from pediatric BFM90 high risk protocol (BFM90 HR). Since all the patients were above the age of 10, they were all considered as high risk patients ([Table 1](#tab1){ref-type="table"}).

Group 2 (adults protocol group) included patients treated with the adopted regimen from adults BFM protocol (BFM) ([Table 2](#tab2){ref-type="table"}). The 2 protocols were adopted from original protocols by replacing the Daunorubicin (which is not available in our country) with another form of anthracycline. Epirubicin was used in pediatrics protocol whereas Doxorubicin was used in adults\' protocol. Also in pediatrics protocol they changed the high dose Methotrexate from 5 mg/m^2^ to 3 g/m^2^ because they found our pediatrics patients cannot tolerate the original dose. All patients enrolled in the study had complete morphological and immunophenotypical data. Patients who previously received antileukemic treatment or had uncontrolled or severe cardiovascular, hepatic, or renal disease not resulting from ALL and/or severe psychiatric condition were excluded. Also we excluded patients with ALL-L3 (Burkitt\'s-type ALL), t(9 : 22), and T-cell lymphoblastic lymphoma.

The study was approved by the institutional review board, in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975.

2.2. Diagnostic Procedure {#sec2.2}
-------------------------

Morphologic analysis for bone marrow (BM) and peripheral-blood specimens were stained by May-Grünwald-Giemsa. Immunophenotyping was performed by flow cytometry with monoclonal antibodies reactive with B-(CD10, CD19, CD22, sIg, cIg), T-(CD1, CD2, CD3, CD4, CD5, CD7, CD8), and precursor-cell (TdT, HLA-DR, and CD34)-associated antigens. Chromosomal analyses using FISH on BM samples were performed at diagnosis for t(9 : 22) only.

2.3. Treatment and Criteria for Response {#sec2.3}
----------------------------------------

The treatment regimens are shown in Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"}. Patients who achieved CR received consolidation followed by maintenance for 2 years. Hospitalization, management of infections, and transfusion policies were carried out according to the institutional discretion.

CR was defined as the absence of clinical manifestations of ALL accompanied with neutrophil count higher than 1.5 × 10^9^/L, platelet count higher than 150 × 10^9^/L, and hemoglobin levels higher than 100 g/L and morphological examination of bone marrow shows less than 5% of blast cells.

Patients with blast cells in BM greater than 5% at the end of the induction phase were considered induction failures. Overall survival was defined as the time from diagnosis until date of death or censoring patients alive at last follow-up date. Disease-free survival (DFS) was defined as survival without relapse or death from the date of first CR or censoring patients alive in continuous complete remission at last follow-up date. Event-free survival (EFS) was defined as time from diagnosis to the date failure of induction course, the date of relapse, or death or censoring patients alive in continuous complete remission at last follow-up date \[[@B9]\].

3. Statistical Analysis {#sec3}
=======================

Bivariate tests, Mann-Whitney test, and variance analysis were used to compare quantitative variables when appropriate and the *X* ^2^ test was used to assess differences in proportions. All comparisons were two-tailed.

Actuarial curves for DFS and OS were plotted according to the Kaplan-Meier method \[[@B21]\] and were compared by the log-rank test. The statistically significant variables identified in univariate analysis were included in multivariable analyses.

4. Results {#sec4}
==========

4.1. Patient Characteristics {#sec4.1}
----------------------------

We reviewed retrospectively data of 86 patients who received treatment from January 2003 to January 2010; the characteristics of the patients were summarized in [Table 3](#tab3){ref-type="table"}.

The B lineage was accounted for 81% in pediatrics protocol group and 82% in adults protocol group whereas the T lineage was accounted for 19% in the pediatrics protocols group and 18% in the adults one (*P* = 0.091).

The total leucocytes count (TLC) in B lineage ALL was \> 50 × 10^9^ cells/L in 56% in pediatrics protocol group, and 59% in adults protocol group (*P* = 0.049). On the other hand, T lineage ALL showed total TLC count of \>100 × 10^9^ cells/L in 30% in pediatrics protocol group, and 33% in adults one (*P* = 0.045). No significant difference was remarked between the 2 groups regarding other variables like median age and distribution of sex.

4.2. CR Rates {#sec4.2}
-------------

Our results showed higher percentage of patients who achieved CR in the pediatrics protocol group than the adults\' protocol group after first induction (96% versus 89%) ([Table 3](#tab3){ref-type="table"}); only one death was reported during induction in pediatrics protocol group whereas 3 patients died during induction in adults protocol group (*P* = 0.009). No other treatment related deaths were reported in the other phases in both regimens.

Sepsis was the main cause of death in the patient treated with pediatrics protocol and in the 2 patients treated with adults one; however, the third patient in adults protocol group died from CNS hemorrhage.

4.3. Relapse Rate {#sec4.3}
-----------------

In pediatrics protocol group, 10 patients (31%) had relapsed after median followup of 39 months with cumulative incidence of relapse "CIR" (0.401) and standard error "SE" (0.1), 6 patients (60%) had isolated BM relapse, 2 patients (20%) had CNS relapse, and 2 patients (22%) had testicular relapse. Timing of relapse was as follows: 1 patient relapsed during consolidation phases, 1 patient relapsed during the first of year of maintenance, 2 patients relapsed in the second years of maintenance, 3 patients relapsed after one year of finishing maintenance, and 3 patients relapsed after 2 years of maintenance.

During the same period of followup for the adults protocol group, 30 patients had relapsed (55%) with CIR 0.631 and SE 0.06. 24 patients (80%) had isolated BM relapse, 3 patients (10%) had CNS relapse, 3 patients (10%) had CNS and BM relapse, and none of the patients had testicular relapse. Timing of relapse was as follows: 4 patients relapsed during the consolidation phases, 5 patients during maintenance, 4 patients relapsed shortly after maintenance, and 7 patients relapsed after one year of maintenance, 5 patients after 2 years of finishing maintenance, and 4 patients after 3 years of finishing maintenance.

4.4. Dose Intensity {#sec4.4}
-------------------

In pediatrics protocol group, the L-asparaginase dose was 8 times higher than the one used in adults protocol. The cytarabine dose was 4 times higher than the adults\' doses; the Dexamethasone was double the dose used in adults protocol and the vincristine dose is almost the same in the 2 protocols; however the vincristine was included in maintenance phase in the pediatrics protocol but not in the adults one. The Etoposide, Ifosfamide, and high dose of Methotrexate are included in the pediatrics protocol but not in the adults one. The duration of treatment was longer in the pediatrics protocol than it was in the adults one due to the fact that induction and consolidation take about 8 months in pediatrics protocol, while they take 3.5 months in the adults. Also, the duration of admission to hospital was also longer in pediatric protocol and also supportive treatment was more in pediatric regimen.

4.5. Toxicity {#sec4.5}
-------------

The study showed higher incidence grade III and IV neutropenia ([Table 4](#tab4){ref-type="table"}) in pediatrics protocol group which resulted in higher episodes of grade III and IV mucositis; also the frequency of grade III and IV thrombocytopenia was more in pediatrics protocol group. Liver impairment due to L-asparaginase, either in the form of elevated bilirubin levels or in elevated liver enzymes, was significantly higher in pediatrics protocol group. The elevated bilirubin levels occurred in 12 patients (37.5%) in pediatrics protocol group, and in 11 (20.3%) patients in adults protocol group (*P* = 0.001). The elevated liver enzymes occurred in 9 patients (28%) in pediatrics protocol group and in 6 patients (11%) in adults protocol group (*P* = 0.003). However, the liver function tests retained normal levels after median 14 days in pediatric protocol group and 9 days in adults protocol group.

Additionally, there was no significant difference in the number of thromboses related to L-asparaginase that occurred in one patient in pediatric protocol 3% and 2 patients in adults protocol 3.7% in adults group (*P* = 0.091).

4.6. Survival Outcome {#sec4.6}
---------------------

After median 39 months of followup, EFS was significantly higher in patients treated in pediatric protocol group 67% (95% CI, 50%--73%) versus 39% (95% CI, 30%--55%) in the adults protocol group *P* = 0.001; the estimated 5-year DFS was 65% (95% CI, 59%--70%) in pediatrics protocol group versus 41% (95% CI, 35%--48%) in adults protocol group *P* = 0.000 ([Figure 1](#fig1){ref-type="fig"}). Consequently, OS was higher in pediatric protocol group 67% (95% CI, 60%--72%) than adults protocol group 45% (95% CI, 40%--51%) *P* = 0.000 ([Figure 2](#fig2){ref-type="fig"}) ([Table 5](#tab5){ref-type="table"}).

We carried out subanalysis regarding the T lineage groups; the DFS and OS in T-ALL were found to be more than double in pediatrics protocol group compared to that in the adults protocol group 61% versus 25% (*P* = 0.001) and 65% versus 26% (*P* = 0.001), respectively.

5. Discussion {#sec5}
=============

Adolescent and young adults AYAs constitute a particular group of patients who find themselves sandwiched between children and adults and who may be referred to either pediatrics or adults oncologists. Several studies comparing the outcome of AYAs on pediatric and adult protocols demonstrated improved survival for AYAs, who were treated by pediatrics protocols; these findings triggered intense interest in the differences with respect to ALL biology and protocol designs in that age group \[[@B22]--[@B24]\]. However, because the results are controversial \[[@B25]\], we conducted this study to compare the efficacy and outcome of our institute adopted pediatrics and adults protocols (adult BFM and pediatric BFM90-HR).

The clinical characteristics between 2 groups were quite similar regarding B and T phenotype distribution and the number of patients who had elevated TLC.

Our results showed significant high remission rate 96% and significant difference in EFS (*P* = 0.001) and DFS (*P* = 0.000) in pediatric protocol group. This difference was attributed mainly to high CR rate and lower relapse rate in the pediatrics group. This could be explained based on the differences in induction and consolidation courses, between the 2 protocols since pediatrics protocol has double doses of L-asparaginase and it was repeated in higher doses in all 9 phases of consolidation in pediatrics protocol. Our results are in line with Dana-Farber Consortium study, which showed that children aged 9 to 18 years may have benefited from higher doses of L-asparaginase especially those with T-ALL despite the increased related toxicity \[[@B26]\]. Moreover, the pediatrics protocol is more intensified regimen as it contains higher doses of cytarabine than the adults\' protocol in addition to the high doses of Methotrexate which were not included in adults\' protocol. The benefit of this strategy was initially proposed by the Berlin-Frankfurt-Munster study group and then it was established by several other studies \[[@B27]--[@B29]\]. We noted that the incidence of chemotherapy-related toxicity showed higher significant difference in pediatrics protocol due to the use of more intensified regimen especially in the number of episodes of neutropenia, mucositis, and liver impairment. However, these episodes were reversible and they did not increase the number of deaths. The significant difference which we found in the toxicity profile might contradict the results of similar study conducted by Huguet et al. \[[@B20]\] because they used more intensified regimen in adults than the regimen we used, which resulted in similar toxicity profile when compared to their center pediatrics protocol. Moreover, our results disagree with the results from Finland, which showed no significant difference regarding DFS and OS between their pediatrics and adults protocols; we also found that they used more intensified regimen in adults which was very similar to their pediatrics protocol \[[@B25]\].

6. Conclusion {#sec6}
=============

We recommend using intensified pediatrics inspired protocol to treat adolescents with acute lymphoblastic leukemia.
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###### 

Adults adopted BFM regimen.

  ------------------------------------------------------------- ------------- ---- --------------------------------------------------------------------------------
  Prephase if (TLC \> 2.500 cells/mm^3^ and/or oraganomegaly)                       
   Vincristine                                                  2 mg          IV   D1
   Dexamethasone                                                10 mg/m^2^    IV   (D1--7)
  Phase I induction                                                                 
   Vincristine                                                  2 mg          IV   (D1, 8, 15, 22)
   Doxorubicin                                                  45 mg/m^2^    IV   (D1, 8, 15, 22)
   L-asparaginase                                               5000 u/m^2^   IM   (D15--28)
   Dexamethasone                                                10 mg/m^2^    IV   11 days (if patients received prophase 7 days so to complete 4 more days only)
   Methotrexate                                                 15 mg         IT   D1
  Phase II induction                                                                
   Cyclophosphamide                                             650 mg/m^2^   IV   (D1, 14, 28)
   Cytarabine                                                   75 mg/m^2^    IV   (D3, 4, 5, 6 and 9, 10, 11, 12 and 16, 17, 18, 19 and 23, 24, 25, 26)
   Methotrexate                                                 15 mg         IT   Given as 4 weekly (D1, 8, 15, 22)
  Cranial prophylaxis                                                              Irradiation (24 Gy)
   Phase I consolidation                                                            
    Vincristine                                                 2 mg          IV   (D1, 8, 15, 22)
    Doxorubicin                                                 45 mg/m^2^    IV   (D1, 8, 15, 22)
    Dexamethasone                                               10 mg/m^2^    IV   For 11 days
   Phase II consolidation                                                           
    Cyclophosphamide                                            650 mg/m^2^   IV   (D1, 14, 28)
    Cytarabine                                                  75 mg/m^2^    IV   (D3, 4, 5, 6 and 9, 10, 11, 12 and 16, 17, 18, 19 and 23, 24, 25, 26)
    Methotrexate                                                15 mg         IT   4 weekly (D1, 8, 15, 22)
  Maintenance will be given for two years                                           
   6-Mercaptopurine                                             75 mg/m^2^    PO   Daily PO
   Methotrexate                                                 20 mg/m^2^    IV   Once weekly
   Triple IT cytarabine 40 mg, MTX 15 mg, Dexamethasone 4 mg                       Every 2 months till the end of maintenance
  ------------------------------------------------------------- ------------- ---- --------------------------------------------------------------------------------

D: Day, Gy: Gray, IT: intrathecal, MTX: Methotrexate, PO: per oral, TLC: total leucocytes count.

###### 

Pediatric adopted BFM90 high risk.

  ----------------------------------------------------------------------------------------------------------------------- --------------- ---- --------------------------------------------
  Prephase                                                                                                                                      
   Prednisolone                                                                                                           60 mg/m^2^      PO   (D1--7)
  Induction                                                                                                                                     
   Prednisolone                                                                                                           60 mg/m^2^      PO   (D1--28)
   Vincristine                                                                                                            1.5 mg/m^2^     IV   (D8, 15, 22, 29)
   Epirubicin                                                                                                             30 mg/m^2^      IV   (D8, 15, 22, 29)
   L-asparaginase                                                                                                         10.000 u/m^2^   IM   (D19, 22, 25, 28, 31, 34, 37, 40)
   Triple age adjusted IT                                                                                                                 IT   (D8, 15, 22, 29)
  High risk I (HRI)                                                                                                                             
   Dexamethasone                                                                                                          20 mg/m^2^      PO   (D1--5)
   Vincristine                                                                                                            1.5 mg/m^2^     IV   (D1--5)
   6-Mercaptopurine                                                                                                       25 mg/m^2^      PO   (D1--5)
   MTX (6 HR infusion)                                                                                                    3 g/m^2^        IV   (D1)
   L-asparaginase                                                                                                         25.000 u/m^2^   IM   (D6)
   Triple age adjusted IT                                                                                                                 IT   (D1)
  High risk II (HRII)                                                                                                                           
   Dexamethasone                                                                                                          20 mg/m^2^      PO   (D1--5)
   Vincristine                                                                                                            1.5 mg/m^2^     IV   (D1)
   Ifosfamide                                                                                                             400 mg/m^2^     IV   (D1--5)
   MTX (6 HR infusion)                                                                                                    3 g/m^2^        IV   (D1)
   Epirubicin                                                                                                             50 mg/m^2^      IV   (D5)
   L-asparaginase                                                                                                         25.000 u/m^2^   IM   (D6)
   Triple age adjusted IT                                                                                                                 IT   (D1)
  High risk III (HRIII)                                                                                                                         
   Dexamethasone                                                                                                          20 mg/m^2^      PO   (D1--5)
   Vincristine                                                                                                            5 mg/m^2^       IV   (D1)
   Cytarabine                                                                                                             1 g/m^2^/12 h   IV   (D2--5)
   Etoposide                                                                                                              150 mg/m^2^     IV   (D2--5)
   L-asparaginase                                                                                                         25.000 u/m^2^   IM   (D6)
   Triple age adjusted IT                                                                                                                 IT   (D1)
  Total number of HR are 9 cycles; then if the patient is in CR after the 9th, cranial prophylaxis (18 g) will be given                         
                                                                                                                                               
  Maintenance maximum two years with pulses of                                                                                                  
   Vincristine                                                                                                            1.5 mg/m^2^     IV   (D1)
   Prednisolone                                                                                                           40 mg/m^2^      PO   For 7 days every two months
   6-Mercaptopurine                                                                                                       25 mg/m^2^      PO   Daily
   MTX                                                                                                                    20 mg/m^2^      IM   Weekly
   Triple intrathecal (Methotrexate, Ara-C, hydrocortisone)                                                                               IT   Every 2 months till the end of maintenance
  ----------------------------------------------------------------------------------------------------------------------- --------------- ---- --------------------------------------------

D: Day, HR: high risk, Gy: gray, MTX: Methotrexate, PO: per oral.

###### 

Patients\' characteristics.

  Characteristics             Adopted BFM 90 high risk   Adopted BFM for adults             
  --------------------------- -------------------------- ------------------------ ---- ---- -------
  Sex                                                                                        
   Male                       21                         66                       36   67   NS
   Female                     11                         34                       18   33   
  Performance status (ECOG)                                                                  
   0-1                        15                         47                       27   50   0.049
   \>1                        17                         53                       26        
  Median age                  16                                                  17        0.931
   Phenotype                                                                                 
    B lineage                 26                         81                       44   82   0.999
    Early pre-B               4                          15                       3    7    0.001
    Common                    4                          15                       12   27   0.032
    Pre-B                     18                         70                       29   66   0.047
   T lineage                  6                          19                       10   18   0.919
  Total leucocyte count                                                                      
   Median                                                                                    
   T lineage \> 100           2                          33                       4    40   0.045
   B lineage \> 50            18                         56                       26   59   0.049
  Serum LDH level                                                                            
   Normal                     7                          22                       4    6    0.920
   Elevated                   25                         78                       50   92   0.051
  Induction death             1                                                   3         0.009
  CR                          27                         96                       48   89   0.001

CR: complete remission.

###### 

Toxicity profile difference between 2 regimens during induction.

  Toxicity               aBFM 90-HR (%)   aBFM standard (%)   *P* value
  ---------------------- ---------------- ------------------- -----------
  Neutropenia                                                  
   GI-II                 60               70                  0.049
   GIII-IV               40               30                  0.049
  Thrombocytopenia GIV   40               25                  0.003
  Mucositis GIII-GIV     30               20                  0.005
  Thrombotic events      7                6                   0.010
  Liver impairment                                             
   Elevated bilirubin    37               20                  0.001
   Elevated enzyme       28               11                  0.003

###### 

Survival evaluation according to different protocols.

        aBFM 90-HR (%)   aBFM standard (%)   *P* value
  ----- ---------------- ------------------- -----------
  EFS   67               39                  0.001
  DFS   65               41                  0.000
  OS    67               45                  0.000

CR: complete remission, EFS: event-free survival, DFS: disease-free survival, OS: overall survival.
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